AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
AI Tools From UVA Aim to Speed New Drug Discovery
University of Virginia scientists have developed AI tools intended to accelerate the discovery of new drugs. The work adds to a growing academic effort to turn AI into a translational engine that can bridge fundamental biology and therapeutic development.
Why AI Is Reengineering Drug Discovery Around Faster Testing and Better Hypothesis Generation
New analysis argues that AI is changing drug discovery by compressing test cycles and scanning huge data sets for previously hidden disease links. The real breakthrough may be less about replacing scientists and more about helping them explore biological space at a speed humans cannot match alone.
Roche and NVIDIA Build the Pharma Industry’s Largest AI Factory
Roche’s new collaboration with NVIDIA signals how quickly drug development is becoming an infrastructure game, not just a software one. By pairing pharmaceutical data with industrial-scale compute, the companies are betting that AI advantage will come from owning the entire pipeline from model training to candidate selection.
AI Drug Discovery Platforms Are Shifting From Promises to Infrastructure
A new wave of platform launches underscores how drug discovery is becoming a systems-level AI market. Rather than selling a single model, companies are now packaging data, automation, and decision support into integrated discovery engines aimed at global disease burdens.
AI in Drug Discovery: 2025 in Review — Insilico Medicine Hits Phase IIa Milestone
Insilico Medicine achieved the first positive Phase IIa results for a fully AI-designed drug, while the Recursion-Exscientia merger created an end-to-end AI drug discovery platform. Over 200 AI-discovered drugs are now in development.
Insilico and Servier Sign $888 Million AI Cancer Discovery Pact
Insilico Medicine and Servier have entered a cancer R&D collaboration valued at up to $888 million, with Insilico leading AI-driven discovery for challenging oncology targets and Servier handling clinical validation and commercialization. The deal underscores how major drugmakers are increasingly treating AI not as a side capability but as a front-end engine for target selection and molecule generation.
AI Drug Discovery Reaches 173 Active Clinical Programs With New FDA Framework
A comprehensive analysis counts 173 active AI-discovered drug programs in clinical development, supported by an evolving FDA framework for credibility assessment of AI models used in drug discovery.
Five Years On, AlphaFold Shows Why Science May Be AI's Killer App
Five years after its debut, Google DeepMind's AlphaFold has been used by over 3 million researchers in 190+ countries. Fortune examines how it has become AI's most impactful real-world application in science and healthcare.
Google DeepMind CEO Says AI-Designed Drugs Are Entering Clinical Trials
Demis Hassabis announced that pharmaceutical drugs designed by AI at Isomorphic Labs are entering clinical trials, marking a new chapter in AlphaFold's journey from protein structure prediction to active drug design.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.